These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 27052127)
1. Daily Observations of Nebuliser Use and Technique (DONUT) in children with cystic fibrosis. Bos AC; Tiddens HA; Tong Minh K; Heeres I; Overweel-Uijterlinde JL; Kok AE; Andrinopoulou ER; Janssens HM J Cyst Fibros; 2016 Sep; 15(5):645-51. PubMed ID: 27052127 [TBL] [Abstract][Full Text] [Related]
2. Improvement of nebulised antibiotic delivery in cystic fibrosis. Wilson D; Burniston M; Moya E; Parkin A; Smye S; Robinson P; Littlewood J Arch Dis Child; 1999 Apr; 80(4):348-52. PubMed ID: 10086942 [TBL] [Abstract][Full Text] [Related]
3. A randomised controlled trial of breathing modes for adaptive aerosol delivery in children with cystic fibrosis. McCormack P; McNamara PS; Southern KW J Cyst Fibros; 2011 Sep; 10(5):343-9. PubMed ID: 21620782 [TBL] [Abstract][Full Text] [Related]
4. [Pulmonary deposition of colistin aerosols in cystic fibrosis. Comparison of an ultrasonic nebulizer and a pneumatic nebulizer]. Gagnadoux F; Diot P; Marchand S; Thompson R; Dieckman K; Lemarié E; Varaigne F; Maurage C; Baulieu JL; Rolland JC Rev Mal Respir; 1996; 13(1):55-60. PubMed ID: 8650418 [TBL] [Abstract][Full Text] [Related]
5. The use of an alternate side lying positioning strategy during inhalation therapy does not prolong nebulisation time in adults with Cystic Fibrosis: a randomised crossover trial. Dentice RL; Elkins MR; Dwyer GM; Bye PTP BMC Pulm Med; 2018 Jan; 18(1):3. PubMed ID: 29310638 [TBL] [Abstract][Full Text] [Related]
6. Nebuliser systems for drug delivery in cystic fibrosis. Daniels T; Mills N; Whitaker P Paediatr Respir Rev; 2013 Jun; 14(2):98-9. PubMed ID: 23583049 [No Abstract] [Full Text] [Related]
7. Lung function in adult patients with cystic fibrosis after using the eFlow rapid for one year. Naehrig S; Lang S; Schiffl H; Huber RM; Fischer R Eur J Med Res; 2011 Feb; 16(2):63-6. PubMed ID: 21463983 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic and tolerability profiles of tobramycin nebuliser solution 300 mg/4 ml administered by PARI eFlow(®) rapid and PARI LC Plus(®) nebulisers in cystic fibrosis patients. Govoni M; Poli G; Acerbi D; Santoro D; Cicirello H; Annoni O; Ružička J Pulm Pharmacol Ther; 2013 Apr; 26(2):249-55. PubMed ID: 23232039 [TBL] [Abstract][Full Text] [Related]
9. Lung deposition of inhaled tobramycin with eFlow rapid/LC Plus jet nebuliser in healthy and cystic fibrosis subjects. Lenney W; Edenborough F; Kho P; Kovarik JM J Cyst Fibros; 2011 Jan; 10(1):9-14. PubMed ID: 20884302 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and Tolerability of Once Daily Double Dose Tobramycin Inhalation in Cystic Fibrosis Using Controlled and Conventional Nebulization. van Velzen AJ; Bos AC; Touw DJ; Tiddens HA; Heijerman HG; Janssens HM J Aerosol Med Pulm Drug Deliv; 2016 Jun; 29(3):273-80. PubMed ID: 26716357 [TBL] [Abstract][Full Text] [Related]
11. Fungal contamination of nebuliser devices used by people with cystic fibrosis. Peckham D; Williams K; Wynne S; Denton M; Pollard K; Barton R J Cyst Fibros; 2016 Jan; 15(1):74-7. PubMed ID: 26104996 [TBL] [Abstract][Full Text] [Related]
12. Comparison of two tobramycin nebuliser solutions: pharmacokinetic, efficacy and safety profiles of T100 and TNS. Sands D; Sapiejka E; Gąszczyk G; Mazurek H; J Cyst Fibros; 2014 Dec; 13(6):653-60. PubMed ID: 24836961 [TBL] [Abstract][Full Text] [Related]